New gel could soothe painful rash from cancer treatment
NCT ID NCT05639933
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a topical gel called HT-001 for treating skin rashes, dryness, and nail problems caused by EGFR inhibitor cancer drugs. About 152 adults on these cancer therapies will apply the gel daily for 6 weeks. The goal is to see if it reduces rash severity and improves quality of life, with a placebo comparison in the second phase.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HT-001 topical gel
What this could lead to
If it works, this could provide a new treatment option for painful skin rashes caused by certain cancer drugs, helping patients stay on their cancer therapy more comfortably.
What could go wrong
This is an early Phase 2 trial with only 152 participants, so results may not apply to everyone. The gel is topical and has low risk, but it may not work better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for XEROSIS CUTIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centrum Medyczne Pratia Krakow
ACTIVE_NOT_RECRUITINGKrakow, 30-727, Poland
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-••••
-
Gabrail Cancer & Research Center
RECRUITINGCanton, Ohio, 44718, United States
Contact
Contact Phone: •••-•••-••••
-
Hospital Sant Joan de Deu-Fundacio Althaia
ACTIVE_NOT_RECRUITINGManresa, 8243, Spain
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-••••
-
Montefiore Medical Center
RECRUITINGThe Bronx, New York, 10467, United States
Contact
Contact Phone: •••-•••-••••
-
NYU Langone Health
RECRUITINGMineola, New York, 11501, United States
Contact
Contact Phone: •••-•••-••••
-
NZOZ Neuromed M. i M. Nastaj Sp.P
ACTIVE_NOT_RECRUITINGLublin, 20-064, Poland
-
Northwell Physician Partners Dermatology
RECRUITINGNew Hyde Park, New York, 11042, United States
Contact
Contact Phone: •••-•••-••••
-
Regis Clinical Research
RECRUITINGMiami, Florida, 33126, United States
Contact Phone: •••-•••-••••
Contact
-
UC Irvine - Chao Family Cancer Center
RECRUITINGOrange, California, 92868, United States
Contact
Contact
-
UCI Health - CIACC
RECRUITINGIrvine, California, 92612, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact